clavulanic acid has been researched along with moxifloxacin in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Eliopoulos, GM; Souli, M; Wennersten, CB | 1 |
| Cuevas, M; Dolores Alonso, M; González González, E; González-Mancebo, E; Lara Cátedra, C | 1 |
| Cots, JM; Llor, C; Miravitlles, M; Molina, J; Naberan, K | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Chhabra, MS; Mortensen, JE; Motley, WW | 1 |
| Amábile-Cuevas, CF; Arvis, P; Bogner, JR; Cruz-Alcázar, J; Hernández-Oliva, G; Reimnitz, P; Vick-Fragoso, R | 1 |
| Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C | 1 |
| Herath, SC; Maisey, S; Normansell, R; Poole, P | 1 |
1 review(s) available for clavulanic acid and moxifloxacin
| Article | Year |
|---|---|
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Disease Progression; Drug Administration Schedule; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Roxithromycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
2 trial(s) available for clavulanic acid and moxifloxacin
| Article | Year |
|---|---|
Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Aza Compounds; Clavulanic Acid; Female; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Skin Diseases, Bacterial; Treatment Outcome | 2009 |
Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clavulanic Acid; Double-Blind Method; Drug Combinations; Female; Fever; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Quinolines; Risk Factors; Treatment Outcome | 2013 |
10 other study(ies) available for clavulanic acid and moxifloxacin
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens.
Topics: Amoxicillin; Anti-Infective Agents; Aza Compounds; Cefuroxime; Clavulanic Acid; Erythromycin; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Penicillin Resistance; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus; Streptococcus pneumoniae; Streptococcus pyogenes | 1998 |
Simultaneous drug allergies.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clavulanic Acid; Drug Hypersensitivity; Female; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Urticaria | 2002 |
Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Bronchitis, Chronic; Clarithromycin; Clavulanic Acid; Cost of Illness; Cost-Benefit Analysis; Data Collection; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Pilot Projects; Pulmonary Disease, Chronic Obstructive; Quinolines; Treatment Outcome | 2004 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
Eikenella corrodens as a causative agent for neonatal conjunctivitis.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Clavulanic Acid; Conjunctivitis; Drug Administration Schedule; Drug Therapy, Combination; Eikenella corrodens; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Infant; Moxifloxacin; Ophthalmic Solutions; Quinolines; Treatment Outcome | 2008 |